Module 3.2.S — Drug Substance (Full) — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 3.2.S — the full drug substance (active ingredient) section: manufacture, characterization, control, and stability.
Why it exists. Regulators must know exactly what the active molecule is, how it is made, what impurities can arise, and how it is tested and stored. This is the chemistry backbone of the quality dossier.
How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.
Format & governing standard. ICH M4Q · Q6B · Q11 · Q3A(R2)/Q3C(R8)/Q3D · Q5C · Q2(R2) · Q7 (GMP)
Module 3.2.S — Drug Substance (Full) — GLPI-103
| Field | Value |
|---|---|
| Document ID | M3-S |
| Version | 3.0 (full, expanded) |
| Standard | ICH M4Q · Q6B · Q11 · Q3A(R2)/Q3C(R8)/Q3D · Q5C · Q2(R2) · Q7 (GMP) |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]Full drug-substance section (S.1–S.7) for the GLPI-103 active pharmaceutical ingredient. Numerical values (sequence, mass, specifications, batch and stability data) are illustrative but technically representative of a lipidated synthetic-peptide GLP-1/APJ dual agonist.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | CMC | Initial detail |
| 2.0 | 2026-06-29 | CMC | Full S.1–S.7 (schematic) |
| 3.0 | 2026-06-30 | CMC | Expanded — explicit structure/MW, SPPS process & IPCs, named impurities, full specification with limits, batch & stability datasets, degradation kinetics |
S.1 General Information
- S.1.1 Nomenclature: GLPI-103 (development code); INN proposed; CAS (to be assigned). Chemical class: synthetic, lipidated, linear analogue peptide acting as a dual agonist of the human GLP-1 receptor (GLP-1R) and the apelin receptor (APJ).
- S.1.2 Structure: a 39-amino-acid single-chain peptide bearing (i) α-aminoisobutyric acid (Aib) at positions 2 and 13 to confer dipeptidyl-peptidase-4 (DPP-4) and general protease resistance, (ii) a C18 fatty di-acid (octadecanedioic acid) albumin-binding moiety conjugated to the Lys²⁰ ε-amine through a γ-Glu + 2×AEEA (8-amino-3,6-dioxaoctanoic acid) spacer to extend plasma half-life, and (iii) a C-terminal amidation. The APJ pharmacophore is engineered into the C-terminal domain. Molecular formula ≈ C₂₂₁H₃₄₈N₅₄O₆₈ ; average molecular mass ≈ 4,914 Da (monoisotopic ≈ 4,911 Da). One intramolecular lactam bridge stabilises the helical segment.
- S.1.3 General properties: white to off-white lyophilised powder; freely soluble in water and aqueous buffers at pH ≥ 7.0, sparingly soluble at the isoelectric point (pI ≈ 4.7); hygroscopic; specific optical rotation and UV (λmax ≈ 280 nm, Trp/Tyr) characteristic; supplied as the acetate salt.
S.2 Manufacture
- S.2.1 Manufacturer(s): named GMP manufacturing site(s) operating under ICH Q7.
- S.2.2 Description of manufacturing process and process controls (Q11):
- Solid-phase peptide synthesis (Fmoc/tBu) on a low-loading resin, stepwise coupling with DIC/Oxyma activation; selected difficult couplings performed as pre-formed dipeptide fragments to control deletion sequences.
- On-resin side-chain conjugation of the γ-Glu–2×AEEA–C18-diacid lipid to the Lys²⁰ side chain (orthogonal ivDde deprotection).
- Global cleavage/deprotection (TFA/scavenger cocktail) and ether precipitation of crude peptide.
- Preparative reversed-phase HPLC purification (C18, acetonitrile/aqueous TFA then acetate salt exchange) and lyophilisation.
- Critical process parameters / in-process controls (IPCs): coupling completion (Kaiser/chloranil, ninhydrin ≤ 0.5% free amine); crude purity by RP-HPLC; main-pool purity ≥ 95.0% with single max impurity ≤ 1.0% before lyophilisation; residual TFA after salt exchange.
- S.2.3 Control of materials: Fmoc-amino acids, resin, reagents and solvents controlled to compendial/internal specifications; TSE/BSE-free declarations for any animal-derived material (none used).
- S.2.4 Controls of critical steps and intermediates: defined acceptance criteria for the crude peptide and the purified intermediate.
- S.2.5 Process validation/evaluation: prospective validation at registration scale (≥ 3 consecutive batches) — see M3-PV.
- S.2.6 Manufacturing development history: scale-up from discovery (solution-assisted) to commercial SPPS; comparability assessed across changes per ICH Q5E principles.
S.3 Characterisation
- S.3.1 Elucidation of structure: primary structure confirmed by high-resolution LC-MS (intact mass and reduced), tryptic/Glu-C peptide mapping with MS/MS, total amino-acid analysis, N-terminal Edman sequencing and C-terminal characterisation; site of lipidation confirmed by MS/MS; higher-order structure by circular dichroism (α-helical content) and analytical SEC.
- S.3.2 Impurities: process-related — single amino-acid deletion (des-Gly, des-Ser) and insertion sequences, D-/epimerised residues, incomplete-acylation (des-lipid) species, oxidation (Met/Trp), deamidation (Asn→isoAsp), acetylation/trifluoroacetylation, and residual reagents/solvents; product-related — dimers/aggregates and the diketopiperazine N-terminal truncation. Each impurity ≥ identification threshold is structurally characterised and toxicologically qualified (Q3A).
S.4 Control of Drug Substance
S.4.1 Specification (illustrative)
| Attribute | Method | Acceptance criterion |
|---|---|---|
| Appearance | Visual | White to off-white powder |
| Identity | RP-HPLC retention + intact-mass MS + peptide map | Conforms to reference |
| Assay (anhydrous, acetate-free) | RP-HPLC (UV 214/280 nm) | 95.0–105.0% |
| Related substances — any single | RP-HPLC (stability-indicating) | ≤ 0.5% |
| Related substances — total | RP-HPLC | ≤ 2.0% |
| des-lipid impurity | RP-HPLC | ≤ 0.5% |
| High-molecular-weight species (aggregates) | SE-HPLC | ≤ 1.0% |
| Peptide content | quantitative AAA / N | 90.0–100.0% (on dried basis) |
| Acetate (counter-ion) | ion chromatography | 4.0–9.0% |
| Residual TFA | ion chromatography / ¹⁹F-NMR | ≤ 0.3% |
| Water content | Karl Fischer | ≤ 8.0% |
| Residual solvents (ACN, DCM, ether, TFA) | GC headspace | ICH Q3C limits |
| Elemental impurities | ICP-MS | ICH Q3D limits |
| Bacterial endotoxins | LAL (kinetic) | ≤ 5 EU/mg |
| Bioburden | compendial | ≤ 10 CFU/g |
| Biological potency — GLP-1R | cAMP functional cell assay | 80–125% of reference |
| Biological potency — APJ | cAMP/β-arrestin functional assay | 80–125% of reference |
S.4.2–S.4.3 Analytical procedures & validation
Procedures validated per ICH Q2(R2) (specificity incl. forced-degradation peak purity, accuracy, repeatability/intermediate precision, linearity, range, LOD/LOQ, solution stability, robustness); details in M3-AMV.
S.4.4 Batch analyses
| Batch | Scale | Assay (%) | Total RS (%) | Max single (%) | Aggregates (%) | GLP-1R potency | APJ potency | Disposition |
|---|---|---|---|---|---|---|---|---|
| DS-001 | Pilot (50 g) | 99.2 | 1.1 | 0.34 | 0.4 | 103% | 98% | Released |
| DS-002 | Pilot (50 g) | 99.5 | 0.9 | 0.28 | 0.3 | 101% | 102% | Released |
| DS-003 | Registration (2 kg) | 99.4 | 1.0 | 0.31 | 0.4 | 99% | 97% | Released |
| DS-004 | Registration (2 kg) | 99.1 | 1.2 | 0.36 | 0.5 | 104% | 101% | Released |
S.4.5 Justification of specification
Limits are justified by manufacturing capability (batch data), the stability-study degradation profile, toxicological qualification of individual and total impurities (Q3A), potency–efficacy linkage, and compendial requirements; the assay and related-substance methods are stability-indicating (forced degradation: acid/base hydrolysis, oxidation H₂O₂, thermal, photolytic, all with peak-purity confirmation).
Impurity investigation (QA-003 ISS-011): an early development lot showed a des-Gly deletion-sequence impurity at 0.18% (above the identification threshold). Root cause = incomplete coupling at a sterically hindered residue. The lot was re-purified and the impurity was structurally characterised and toxicologically qualified (Q3A); CAPA changed the difficult coupling to a pre-formed dipeptide fragment and added a coupling-completion IPC (M3-CS §2), which controls the impurity to ≤0.10% in subsequent batches.
S.5 Reference Standards or Materials
A fully characterised primary reference standard (orthogonal mass, sequence, potency, water/counter-ion) and a qualified working standard bracketed against it; requalification on a defined interval and on each new lot.
S.6 Container Closure System
Drug substance stored in double low-density-polyethylene (LDPE) liners within an HDPE drum, with desiccant, protected from light; extractable/leachable and moisture-protection suitability demonstrated.
S.7 Stability (Q1A(R2)/Q5C)
Stability-indicating RP-HPLC (assay, related substances) and SE-HPLC (aggregates) on registration batches:
| Condition | Time | Assay | Total RS | Aggregates | Conclusion |
|---|---|---|---|---|---|
| −20 °C (long-term) | 0 / 12 / 24 mo | 99.4 → 99.1 → 98.8% | 1.0 → 1.2 → 1.4% | 0.4 → 0.5 → 0.6% | within spec |
| 5 °C | 0 / 6 / 12 mo | 99.4 → 99.0 → 98.4% | 1.0 → 1.5 → 2.0% | 0.4 → 0.6 → 0.9% | supports excursions |
| 25 °C/60% RH (accelerated) | 0 / 3 / 6 mo | 99.4 → 98.1 → 96.9% | 1.0 → 2.4 → 3.6% | 0.4 → 1.0 → 1.7% | trend; informs handling |
Principal degradation pathways are oxidation (Met/Trp), deamidation (Asn), and aggregation, all controlled by the specification and the recommended −20 °C storage with a 24-month re-test period (full dataset in M3-STAB).
Comments (0)
No comments yet. Be the first to say something!